Ken Griffin
ERNA icon

Ken Griffin’s Eterna Therapeutics ERNA Stock Holding History

Ken Griffin’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$216K – 14028
2021
Q3 		$216K Sell
3
-12
-80% -$1.04M ﹤0.01% 11825
2021
Q2 		$2.07M Buy
+15
New +$2.16M ﹤0.01% 6536

Other funds holding ERNA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $78.6B AUM 28.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ken Griffin's ERNA Position: Q1 2026 in Review

Ken Griffin opened a new position in Eterna Therapeutics (ERNA) in Q1 2026: 1,323 shares worth $6.58K. The stake represents ﹤0.01% of the portfolio and ranks #12796 among its holdings. This is a return to the name: Ken Griffin previously reported a position in ERNA as recently as Q1 2025.

Ken Griffin first reported a position in ERNA in Q3 2018 and has held it in 13 quarters since. The position peaked at $490K in Q4 2021. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

  • Ken Griffin held 1,323 shares of Eterna Therapeutics worth $6.58K as of Q1 2026.
  • Eterna Therapeutics was a new Ken Griffin position in Q1 2026.
  • Eterna Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12796 holding.
  • Ken Griffin first reported a position in Eterna Therapeutics in Q3 2018 and has held it in 13 quarters since.
  • Ken Griffin's Eterna Therapeutics position peaked at $490K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.